AN2 Therapeutics is a small Menlo Park biopharma that has spent the past year rebuilding itself from a single failed trial, and the second-quarter print is the moment that bet is supposed to start paying off. The company reported a second-quarter net loss of $8.2 million on essentially zero revenue and held $79.9 million in cash and investments at June 30, 2026, a balance that management has guided sustains operations into 2029. The story of the quarter is not the loss; the loss is mechanical for a clinical-stage biotech with three Phase 2 trials in start-up. The story is that ANTX has, in the span of fourteen months, converted a single non-tuberculous mycobacterial asset whose Phase 2/3 study failed on its primary endpoint in May 2025 into a three-program pipeline - epetraborole in polycythemia vera and in M. abscessus lung disease, plus an oral Chagas candidate from the same boron chemistry engine that produced the original molecule.
The thesis is that the boron chemistry platform is the asset, and the pipeline is the proof. Epetraborole is a leucyl-tRNA synthetase inhibitor that the company licenses from Anacor, a wholly owned Pfizer subsidiary, and the molecule has now generated clinical signals in three different diseases, including the M. abscessus program where no FDA-approved therapy exists. The Chagas program is built on a different target entirely, cleavage and polyadenylation specificity factor 3, where ANTX's lead oral compound AN2-502998 produced 100% parasitic elimination in non-human primates with naturally acquired chronic infection in June 2026. The equity is the platform call, not the lead asset.
The load-bearing risk is execution density. ANTX is running three Phase 2 trials simultaneously with a team of 21 full-time employees, and the EBO-PV-201 sentinel cohort in polycythemia vera does not begin enrollment until the fourth quarter of 2026, with the company guiding to periodic Part 1 data throughout 2027. The falsifiable clock is the third quarter of 2026: the IND filing for the polycythemia vera program is expected within weeks, and management expects to initiate a Phase 2 study of AN2-502998 in chronic Chagas disease in late 2026. If either milestone slips, the platform thesis loses operational evidence; if both land, the market has to re-rate the equity from a $208 million microcap to something closer to the cash-and-platform sum that comparable clinical-stage infectious disease names trade at.